FidoCure Leads Canine Cancer Research with the World’s Largest Canine Cancer Database

At FidoCure, we're committed to transforming cancer care for dogs through precision medicine. Our journey began with a mission to address a critical gap in canine cancer research and treatment. Prior to 2019, the field of canine cancer genomics lagged significantly behind its human counterpart. With only 2,000 canine tumor samples sequenced worldwide (compared to 20,000 human samples), the potential for precision medicine in veterinary oncology remained largely untapped.

Recognizing this unmet need, FidoCure set out to build the world's largest dataset of canine cancer genomics. Our efforts have led to remarkable progress. In 2023, we published a study detailing the genomic sequencing of 671 naturally occurring canine tumors. This study not only expanded our understanding of canine cancer but also positioned dogs as a valuable translational model for human cancer research. Our innovative approach ensures that each dog enrolled in our program benefits from the collective knowledge gained from all previous participants.

Building on this initial success, FidoCure has rapidly expanded its reach and impact. A 2023 study published in Nature Precision Oncology utilized our platform to enroll 2,119 dogs with cancer, further demonstrating the potential of our approach. Today, the FidoCure platform includes data from over 5,000 dogs, reflecting our commitment to transforming cancer care for our canine companions.

FidoCure's precision medicine approach leverages advanced genomic sequencing and real-world data from dogs with naturally occurring cancers. This empowers pet owners and veterinarians with crucial insights for making informed treatment decisions. We identify specific genetic mutations driving each patient's cancer, which may benefit from small-molecule targeted drugs. Our personalized solutions can lead to better outcomes, fewer side effects, and improved quality of life for dogs. Moreover, we analyze vast amounts of genomic, clinical, and environmental data to uncover patterns and insights that inform more effective, tailored treatment strategies.

FidoCure has successfully brought canine cancer genomic sequencing out of the lab and into real-world clinical settings. Our advanced tools allow veterinary partners to identify the specific genetic alterations underlying a pet's cancer, select targeted therapies to disrupt cancer pathways effectively, and continuously improve treatment strategies based on ongoing data analysis.

By studying real-world cases, FidoCure is paving the way for more effective and targeted therapies, accelerating the development of precision oncology treatments for canine cancer, and contributing to the broader field of oncology, potentially benefiting both canine and human patients. As we continue to expand our dataset, the promise of more personalized and effective cancer care for dogs grows stronger. At FidoCure, we're committed to a future where every dog with cancer has access to the most advanced, tailored treatments available.